Search the Newsreel

Cinemark (CNK) Upgraded to Strong Buy: Here's What You Should Know

Investors might want to bet on Cinemark Holdings (CNK), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock …

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

Generate Biomedicines (NASDAQ: GENB) is one of the top five largest holdings of Nvidia (NASDAQ: NVDA), run by CEO Jensen Huang. Let that sink in for a moment. The largest publicly traded company by market capitalization has roughly $10.4 million invested in a clinical-stage …

Cincinnati Financial (CINF) Beat On Earnings, Is The Stock Fully Priced?

nCino (NCNO) insider Jeanette Sellers files Form 144 to sell 1,536 shares

nCino, Inc. insider Jeanette E. Sellers has filed a Form 144 to sell 1,536 shares of common stock, valued at $29,998.08, through Fidelity Brokerage Services on NASDAQ. These shares are part of restricted stock that vested on August 1, 2026, received as compensation. The …

Revolution Medicines stock hits all-time high of 195.48 USD By Investing.com

Revolution Medicines Inc. (RVMD) has reached an all-time stock high of $195.48, reflecting significant investor confidence with a 1-year price return of 403.93%. Despite an InvestingPro analysis suggesting the stock is overvalued, analysts from UBS, Mizuho, Wedbush, and Truist Securities have raised price targets …

nCino (NCNO) insider Sean Desmond plans 11,815-share stock sale after equity vesting

nCino (NCNO) insider Sean Desmond has filed a Form 144 notice to sell 11,815 shares of common stock, valued at approximately $231,460.61. This proposed sale includes shares from restricted stock vesting and a stock option exercise, both occurring in early August 2026. Desmond has …

Everest Medicines Ltd. Revenue Breakdown – HKEX:1952

Cintas splits CEO and president roles, promotes 27-year veteran to new position

Cintas Corp. has announced a change in its C-suite structure, splitting the roles of CEO and president. This move involves promoting a 27-year veteran executive to the newly designated president position. The Cincinnati Business Courier reported on this development.

Sei Investments Co. Sells 8,979 Shares of Cincinnati Financial Corporation $CINF

Sei Investments Co. reduced its stake in Cincinnati Financial Corporation (NASDAQ:CINF) by 18.3% in the first quarter, selling 8,979 shares and retaining 40,200 shares valued at $6.33 million. Despite missing quarterly earnings estimates, the company reported strong revenue and analysts maintain a "Moderate Buy" …

Lipocine Q2 2026 earnings: Missing license revenue drives top-line decline

Lipocine (NASDAQ: LPCN) reported a significant decline in Q2 2026 revenue to $190,099, primarily due to the absence of license revenue from the prior year, though TLANDO royalties increased. The company's net loss widened to $2.6 million, and attention is now focused on an …

Beone Medicines Ag Raises Earnings Guidance for 2026

TYK Medicines Schedules Board Meeting to Approve Interim Results and Consider Dividend

Editas Medicine (EDIT) Earnings Date and Reports 2026 $EDIT

Editas Medicine earnings beat by $0.12, revenue topped estimates

Lipocine Inc (LPCN) Earnings Date & Reports & Earnings News

Revolution Medicines (RVMD) Earnings Date and Reports 2026

China Cinda Warns of First-Half Profit Drop as Property Slump Weighs

U.S. cinema ad platform operator sets Aug. 11 earnings call

National CineMedia, Inc. (NASDAQ: NCMI) announced that it will release its second quarter 2026 earnings results after the market closes on Tuesday, August 11, 2026. A conference call and audio webcast to discuss these results will follow at 5:00 p.m. Eastern Time. The company …

National CineMedia Inc (NCMI) CFO Ronnie Ng Sells 1,000 Shares

National CineMedia Inc's CFO, Ronnie Ng, sold 1,000 shares of NCMI stock on August 3, 2026, for $4.05 per share, bringing his total sales over the past year to 160,726 shares with no purchases. Despite this insider selling, the stock is considered "Fairly Valued" …

Editas Medicine (EDIT) Projected to Post Quarterly Earnings on Tuesday

Editas Medicine (EDIT) is expected to announce its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts forecasting a loss of $0.30 per share and $2.85 million in revenue. The company's previous quarter showed a narrower-than-expected loss but significantly missed revenue …

A cardiovascular leader joins Editas as a director steps down

Editas Medicine has appointed Dr. Patrick T. Ellinor, a renowned leader in cardiovascular medicine and human genetics, to its Board of Directors, effective August 6, 2026. Dr. Ellinor's expertise is expected to significantly contribute to the advancement of EDIT-401 for hyperlipidemia and the company's …

Editas Medicine appoints Patrick Ellinor to board of directors

Editas Medicine has appointed Patrick T. Ellinor, M.D., Ph.D., to its Board of Directors, effective August 6. Dr. Ellinor brings extensive experience in human genetics and cardiovascular research from his roles at Mass General Brigham Heart and Vascular Institute and the Broad Institute. He …

CINCINNATI FINANCIAL CORPORATION : KBW CUTS TARGET PRICE TO $190 FROM $201

KBW has reduced its target price for Cincinnati Financial Corporation (CINF.O) from $201 to $190. This news was reported by Reuters on August 5, 2026. The article reiterates this information, noting that the content reflects the author's opinion and is not investment advice.

nCino (NCNO) insider Sean Desmond files to sell 28,675 shares after vesting

nCino executive Sean Desmond has filed to sell 28,675 shares of common stock through Fidelity Brokerage Services LLC, following a restricted stock vesting on August 3, 2026. The aggregate market value of these shares is estimated at $551,079.01. Desmond has also made several other …

nCino (NCNO) insider Gregory Orenstein plans sale of 11,780 shares

nCino, Inc. insider Gregory Orenstein has filed to sell 11,780 common shares of NCNO through Fidelity Brokerage Services LLC on or about August 4, 2026, with an aggregate market value of $226,389.21. These shares are related to restricted stock acquired as compensation on August …

nCino (NCNO) leader Pierre Naudé plans sale of vested stock

nCino (NCNO) insider Pierre Naudé has filed a Form 144 notice to sell 4,677 common shares acquired through restricted stock vesting. The planned sale, valued at $89,883.05, is scheduled for August 4, 2026, via Fidelity Brokerage Services. This filing also discloses a previous sale …

Cintas Target of Unusually Large Options Trading (NASDAQ:CTAS)

Cintas (NASDAQ:CTAS) experienced unusually high options trading volume, with traders acquiring 4,665 call options, a 196% increase over the typical daily volume. This activity follows the company's strong financial performance, beating earnings and revenue estimates, raising its dividend, and receiving positive analyst upgrades and …

29 New Praxis Employees Get Stock Units, Four-Year Vesting

Praxis Precision Medicines (PRAX) announced the grant of restricted stock unit (RSU) awards covering 7,318 common shares to 29 new non-executive employees. These inducement grants, made under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4), will vest in four equal annual installments, contingent …

Director Schiff sells 7,600 Cincinnati Financial (CINF) shares

Cincinnati Financial director Charles Odell Schiff reported an indirect sale of 7,600 shares of common stock on August 3, 2026, by a charitable foundation at $175.4036 per share. Following the transaction, the foundation holds 173,455 shares, while Schiff maintains significant direct and indirect holdings …

Cincinnati Financial Insider Sold Shares Worth $1,333,067, According to a Recent SEC Filing

An insider at Cincinnati Financial Corporation sold shares valued at $1,333,067, as disclosed in a recent SEC filing. This transaction occurred on August 4, 2026. The article notes recent analyst rating adjustments for Cincinnati Financial, including BMO Capital maintaining an Outperform rating and BofA …

Lipocine Inc (NASDAQ: LPCN) Share Price, LPCN Stock News, LPCN Share Price & Updates

This article provides a comprehensive overview of Lipocine Inc. (NASDAQ: LPCN), including its current stock price, fundamental financial data, and peer comparison. It details the company's income statement, balance sheet, and cash flow for several years, highlighting its clinical-stage biopharmaceutical focus on CNS disorders …

Lipocine reports Q2 net loss $2.6M, cash and investments $23.3M as of June 30, 2026

Lipocine (LPCN) reported a Q2 2026 net loss of $2.6 million, or ($0.32) per diluted share, with $23.3 million in cash and investments as of June 30, 2026. The company generated $190,099 in total revenue from TLANDO royalty income. Key business highlights include progress …

Lipocine Inc. Q2 2026: Revenue $190099 EPS $(0.32) — 10-Q Summary

Lipocine Inc. reported its Q2 2026 financial results, with revenue of $190,099 and a net loss of $(2,622,595), resulting in a diluted EPS of $(0.32). Revenue significantly declined year-over-year due to a shift in revenue mix, despite progress in pipeline development and capital raising …

Lipocine Inc. (LPCN) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive financial information for Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company. It includes real-time stock price data, historical performance, key financial metrics, an overview of the company's drug pipeline and research focus, and recent analyst insights. The company specializes …

Disc Medicine, Inc. Revenue Breakdown – NASDAQ:IRON

The article provides a financial overview of Disc Medicine, Inc. (NASDAQ:IRON) on TradingView, focusing on its revenue breakdown and other fundamental statistics. It highlights sections for statements, dividends, earnings, and segment performance. The content indicates that the market was closed at the time of …

Here is Why Growth Investors Should Buy Cinemark (CNK) Now

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all. That's because, these stocks usually carry above-average risk …